Relmada Therapeutics Announces The Appointment Of Urology Expert Dr. Raj S. Pruthi as Chief Medical Officer Of Urology Division

Relmada Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for oncology and central nervous system disorders, has appointed Dr. Raj S. Pruthi as Chief Medical Officer for Urology. In this role, Dr. Pruthi will lead the medical strategy and clinical development of NDV-01, Relmada’s investigational therapy for non-muscle invasive bladder cancer (NMIBC). His appointment comes shortly after the company shared encouraging initial Phase 2 results for NDV-01 at the American Urology Association (AUA) 2025 Annual Meeting on April 28, 2025.

Sergio Traversa, Chief Executive Officer, Relmada, stated, “We are very pleased to welcome Raj to Relmada. As we prepare to begin registrational studies, we believe Raj’s extensive clinical experience will play a vital role in the NDV-01 program’s success. Additionally, we have a strong belief that Raj’s first-hand understanding of approved bladder cancer therapies and the clinical evidence that is required for widespread physician adoption of new therapies will be a significant asset for Relmada.”

Dr. Pruthi, CMO, Relmada, mentioned, “Advancing innovative, bladder-sparing treatments for bladder cancer has been the focus of my career. I joined Relmada because I believe NDV-01 has the unique potential to become a class-leading therapy for the treatment of NMIBC. Current treatments are complex to administer and burdensome for patients. Promising Phase 2 data presented at AUA 2025 showed that NDV-01’s gemcitabine/docetaxel (GEM/DOCE) sustained release formulation produced impressive response rates, with favorable overall tolerability, in a simple ready-to-use administration. I am enthusiastic about working with my colleagues at Relmada to achieve our goal of initiating the Phase 3 trial in H1 2026 and bringing NDV-01 to patients with NMIBC as soon as possible.”

Dr. Pruthi brings over 25 years of experience in academic and industry settings, with a focus on urologic oncology, clinical trials, and robotic surgery. He has been actively involved in shaping clinical practice through his work on the American Urological Association’s guidelines for NMIBC. His experience includes leading clinical programs and global medical affairs in both early- and late-stage development.

Before joining Relmada, Dr. Pruthi served as Chief Medical Officer at enGene Holdings Inc., where he guided urologic oncology programs, and previously held a senior leadership role in Global Medical Affairs at Johnson & Johnson Innovative Medicine. His proven ability to design and manage large-scale bladder cancer studies and his clinical expertise will support the advancement of NDV-01 and future urology-focused programs at Relmada.